Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muhammad Shariq Usman

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
Nature Reviews. Cardiology|May 17, 2022
The need for increased pragmatism in cardiovascular clinical trialsMuhammad Shariq Usman, Harriette G C Van Spall, Stephen J Greene, et al.
Current Problems in Cardiology|April 23, 2023
Association of Electronic Cigarette Exposure on Cardiovascular Health: A Systematic Review and Meta-AnalysisTariq Jamal Siddiqi, Ahmed Mustafa Rashid, Ahmed Kamal Siddiqi, et al.
JACC. Heart Failure|April 28, 2023
Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure: The GUIDE-IT TrialMuhammad Shahzeb Khan, Sumitabh Singh, Matthew W Segar, et al.
JAMA Cardiology|May 24, 2023
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved TrialJaved Butler, Muhammad Shariq Usman, Gerasimos Filippatos, et al.
Circulation|November 11, 2023
Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: A Pooled Cohort AnalysisKershaw V Patel, Matthew W Segar, David C Klonoff, et al.
Journal of the American College of Cardiology|June 21, 2023
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient PopulationsMuhammad Shariq Usman, Tariq Jamal Siddiqi, Stefan D Anker, et al.
Nature Medicine|July 2, 2026
Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trialAmbarish Pandey, Neil Keshvani, Syed K Rizvi, et al.
European Journal of Heart Failure|October 17, 2022
Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrumJaved Butler, Muhammad Shariq Usman, Kevin J Anstrom, et al.
European Heart Journal|April 26, 2023
Leveraging electronic health records to streamline the conduct of cardiovascular clinical trialsMuhammad Shahzeb Khan, Muhammad Shariq Usman, Khawaja M Talha, et al.
Nature Medicine|December 5, 2022
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-PreservedStefan D Anker, Javed Butler, Muhammad Shariq Usman, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
Nature Reviews. Cardiology|May 17, 2022
The need for increased pragmatism in cardiovascular clinical trialsMuhammad Shariq Usman, Harriette G C Van Spall, Stephen J Greene, et al.
Current Problems in Cardiology|April 23, 2023
Association of Electronic Cigarette Exposure on Cardiovascular Health: A Systematic Review and Meta-AnalysisTariq Jamal Siddiqi, Ahmed Mustafa Rashid, Ahmed Kamal Siddiqi, et al.
JACC. Heart Failure|April 28, 2023
Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure: The GUIDE-IT TrialMuhammad Shahzeb Khan, Sumitabh Singh, Matthew W Segar, et al.
JAMA Cardiology|May 24, 2023
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved TrialJaved Butler, Muhammad Shariq Usman, Gerasimos Filippatos, et al.
Circulation|November 11, 2023
Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: A Pooled Cohort AnalysisKershaw V Patel, Matthew W Segar, David C Klonoff, et al.
Journal of the American College of Cardiology|June 21, 2023
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient PopulationsMuhammad Shariq Usman, Tariq Jamal Siddiqi, Stefan D Anker, et al.
Nature Medicine|July 2, 2026
Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trialAmbarish Pandey, Neil Keshvani, Syed K Rizvi, et al.
European Journal of Heart Failure|October 17, 2022
Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrumJaved Butler, Muhammad Shariq Usman, Kevin J Anstrom, et al.
European Heart Journal|April 26, 2023
Leveraging electronic health records to streamline the conduct of cardiovascular clinical trialsMuhammad Shahzeb Khan, Muhammad Shariq Usman, Khawaja M Talha, et al.
Nature Medicine|December 5, 2022
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-PreservedStefan D Anker, Javed Butler, Muhammad Shariq Usman, et al.
Pageof 12